Compare BAND & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | PRTC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.6M | 386.7M |
| IPO Year | 2017 | N/A |
| Metric | BAND | PRTC |
|---|---|---|
| Price | $14.73 | $16.79 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $20.80 | N/A |
| AVG Volume (30 Days) | ★ 186.8K | 4.7K |
| Earning Date | 10-30-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $756,118,000.00 | $6,391,000.00 |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $15.10 | N/A |
| P/E Ratio | ★ N/A | $7.65 |
| Revenue Growth | 7.42 | ★ 1265.60 |
| 52 Week Low | $11.33 | $13.30 |
| 52 Week High | $21.08 | $23.69 |
| Indicator | BAND | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 50.85 | 51.25 |
| Support Level | $13.75 | $16.42 |
| Resistance Level | $14.46 | $16.83 |
| Average True Range (ATR) | 0.53 | 0.31 |
| MACD | 0.13 | 0.10 |
| Stochastic Oscillator | 87.50 | 58.99 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.